Liquid Biopsy Promise

 Five Reasons It Matters

Podcast Intro and Guests

How the Term Was Born

Can It Cut Costs

Standards and Guidelines

Will Tissue Biopsies Fade

India in Global Trials

Oncology Breakthroughs Now

Immunotherapy and CAR T

Tracking Resistance with Blood

mRNA Vaccines Future

AI in Cancer Research

Closing Thanks and Credits

In 2010, scientists Catherine Alix-Panabières and Klaus Pantel coined the term “liquid biopsy”, which Nature later named one of the key cancer discoveries of the last 20 years. Their blood-based approach can detect cancer early, spare patients painful needle biopsies, help doctors choose the right therapy and flag when a treatment stops working. Professor Pantel says a $1,000 test could save around $10,000 in ineffective treatment. In this conversation with The Economic Times pharma editor Vikas Dandekar, they explain why adoption is still slow, how India can take a bigger role in global clinical trials, and how immunotherapy and AI could shape the future of cancer care. Listen in

In 2010, scientists Catherine Alix-Panabi&egrave;res and Klaus Pantel coined the term &ldquo;liquid biopsy&rdquo;, which Nature later named one of the key cancer discoveries of the last 20 years. Their blood-based approach can detect cancer early, spare patients painful needle biopsies, help doctors choose the right therapy and flag when a treatment stops working. Professor Pantel says a $1,000 test could save around $10,000 in ineffective treatment. In this conversation with The Economic Times pharma editor Vikas Dandekar, they explain why adoption is still slow, how India can take a bigger role in global clinical trials, and how immunotherapy and AI could shape the future of cancer care. Listen in

Liquid Biopsy: Catching Cancer Early With a Simple Blood Test

 In this Morning Brief conversation, Dia Rekhi speaks with political scientist and and researcher at CERI, Sciences Po Paris Gilles Verniers about the wave of youth-led protests sweeping the globe. Starting with France’s student-led movement, they explore why young people anchor these uprisings, whether “Gen Z” is too simple a label, and how economic anxiety, shrinking opportunity and AI-driven job fears connect movements from Paris to Serbia to India’s Cockroach Janata Party. Vernier also discusses electoral conversion, why authenticity beats youth-speak in politics, how AI is reshaping campaigns, and why minority protests remain legitimate in a democracy. He closes by declining to predict where they lead.

Listen In

Check out other interesting episodes like - Cognizant’s Surya Gummadi on How AI Can Deliver Returns, The Future of Insurance in India | Sarbvir Singh of PB Fintech, Groww’s ₹6,600 Cr Leap - Fintech’s Big Market Test Begins , OML CEO on the Creator Economy’s Next Wave & much more.



Catch the latest episode of ‘The Morning Brief’ on The Economic Times Online, Spotify, Apple Podcasts, JioSaavn, Amazon Music and Youtube.

&nbsp;In this Morning Brief conversation, Dia Rekhi speaks with political scientist and and researcher at CERI, Sciences Po Paris Gilles Verniers about the wave of youth-led protests sweeping the globe. Starting with France&rsquo;s student-led movement, they explore why young people anchor these uprisings, whether &ldquo;Gen Z&rdquo; is too simple a label, and how economic anxiety, shrinking opportunity and AI-driven job fears connect movements from Paris to Serbia to India&rsquo;s Cockroach Janata Party. Vernier also discusses electoral conversion, why authenticity beats youth-speak in politics, how AI is reshaping campaigns, and why minority protests remain legitimate in a democracy. He closes by declining to predict where they lead. Listen In Check out other interesting episodes like - <a href="https://podcasts.apple.com/in/podcast/cognizants-surya-gummadi-on-how-ai-can-deliver-returns/id1827451035?i=1000779596143">Cognizant&rsquo;s Surya Gummadi on How AI Can Deliver Returns</a>, <a href="https://podcasts.apple.com/in/podcast/the-future-of-insurance-in-india-sarbvir-singh-of-pb-fintech/id1827451035?i=1000777479937">The Future of Insurance in India | Sarbvir Singh of PB Fintech</a>, <a href="https://podcasts.apple.com/us/podcast/growws-%E2%82%B96-600-cr-leap-fintechs-big-market-test-begins/id1568661777?i=1000735482598">Groww&rsquo;s ₹6,600 Cr Leap - Fintech&rsquo;s Big Market Test Begins</a> , <a href="https://podcasts.apple.com/us/podcast/oml-ceo-on-the-creator-economys-next-wave/id1568661777?i=1000734328149">OML CEO on the Creator Economy&rsquo;s Next Wave</a> &amp; much more. 
Catch the latest episode of &lsquo;The Morning Brief&rsquo; on <a href="https://economictimes.indiatimes.com/podcast?from=mdr">The Economic Times Online</a>,<a href="https://open.spotify.com/show/6PL5kfPbwURBEu6fHCVTOL?si=26ec0fbfa7134fea"> Spotify</a>, <a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777">Apple Podcasts</a>, <a href="https://www.jiosaavn.com/shows/the-morning-brief/1/GNPiFQD2xpY_">JioSaavn</a>, <a href="https://music.amazon.in/podcasts/f378141f-9afb-495d-83da-9b08ec5047ac/the-morning-brief">Amazon Music</a> and <a href="https://www.youtube.com/@theetpodcasts">Youtube</a>.

Why Youth Are Taking to the Streets: From Paris to Belgrade to India

India has become ChatGPT’s largest market by weekly active users. But can OpenAI turn that extraordinary reach into a sustainable business? In this conversation with The Economic Times’ tech editor Surabhi Agarwal, OpenAI India Managing Director Prabhjeet Singh discusses the shift from AI experimentation to enterprise adoption, the challenge of monetising Indian users, and the company’s growing investments in local infrastructure. He also addresses competition from technology giants, the rise of autonomous AI agents, ChatGPT advertising, cybersecurity risks and India’s push for AI sovereignty. As AI valuations soar, can real-world adoption justify the enormous investments being made?

Listen In

You can follow Anirban Chowdhury on his social media: X and Linkedin

Check out other interesting episodes like - Cognizant’s Surya Gummadi on How AI Can Deliver Returns, The Future of Insurance in India | Sarbvir Singh of PB Fintech, Groww’s ₹6,600 Cr Leap - Fintech’s Big Market Test Begins , OML CEO on the Creator Economy’s Next Wave & much more.



Catch the latest episode of ‘The Morning Brief’ on The Economic Times Online, Spotify, Apple Podcasts, JioSaavn, Amazon Music and Youtube.

India has become ChatGPT&rsquo;s largest market by weekly active users. But can OpenAI turn that extraordinary reach into a sustainable business? In this conversation with The Economic Times&rsquo; tech editor Surabhi Agarwal, OpenAI India Managing Director Prabhjeet Singh discusses the shift from AI experimentation to enterprise adoption, the challenge of monetising Indian users, and the company&rsquo;s growing investments in local infrastructure. He also addresses competition from technology giants, the rise of autonomous AI agents, ChatGPT advertising, cybersecurity risks and India&rsquo;s push for AI sovereignty. As AI valuations soar, can real-world adoption justify the enormous investments being made? Listen In You can follow Anirban Chowdhury on his social media:<a href="https://twitter.com/AnirbanET"> X</a> and<a href="https://www.linkedin.com/in/anirban-chowdhury-b5067219/"> Linkedin </a>Check out other interesting episodes like - <a href="https://podcasts.apple.com/in/podcast/cognizants-surya-gummadi-on-how-ai-can-deliver-returns/id1827451035?i=1000779596143">Cognizant&rsquo;s Surya Gummadi on How AI Can Deliver Returns</a>, <a href="https://podcasts.apple.com/in/podcast/the-future-of-insurance-in-india-sarbvir-singh-of-pb-fintech/id1827451035?i=1000777479937">The Future of Insurance in India | Sarbvir Singh of PB Fintech</a>, <a href="https://podcasts.apple.com/us/podcast/growws-%E2%82%B96-600-cr-leap-fintechs-big-market-test-begins/id1568661777?i=1000735482598">Groww&rsquo;s ₹6,600 Cr Leap - Fintech&rsquo;s Big Market Test Begins</a> , <a href="https://podcasts.apple.com/us/podcast/oml-ceo-on-the-creator-economys-next-wave/id1568661777?i=1000734328149">OML CEO on the Creator Economy&rsquo;s Next Wave</a> &amp; much more. 
Catch the latest episode of &lsquo;The Morning Brief&rsquo; on <a href="https://economictimes.indiatimes.com/podcast?from=mdr">The Economic Times Online</a>,<a href="https://open.spotify.com/show/6PL5kfPbwURBEu6fHCVTOL?si=26ec0fbfa7134fea"> Spotify</a>, <a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777">Apple Podcasts</a>, <a href="https://www.jiosaavn.com/shows/the-morning-brief/1/GNPiFQD2xpY_">JioSaavn</a>, <a href="https://music.amazon.in/podcasts/f378141f-9afb-495d-83da-9b08ec5047ac/the-morning-brief">Amazon Music</a> and <a href="https://www.youtube.com/@theetpodcasts">Youtube</a>.

OpenAI's India Bet: From ChatGPT Users to AI-Powered Businesses

India's rapidly expanding financial ecosystem faces a growing cybersecurity challenge. While large banks have invested heavily in protecting their systems, fintech companies and non-banking financial institutions remain vulnerable to increasingly sophisticated attacks. Artificial intelligence is changing the economics of cybercrime, allowing attackers to identify weaknesses faster, at significantly lower costs and on a much larger scale.

Anirban Chowdhury speaks to Yash Kakadia, founder of Security Brigade, about how these attacks work, the vulnerabilities within financial technology infrastructure, the limitations of compliance-driven security, and whether India's regulators and financial institutions can keep pace with an accelerating threat.

You can follow Anirban Chowdhury on his social media: X and Linkedin

Check out other interesting episodes like: How Will a Volatile ₹ Impact You in 2026?, How Quick Commerce is Triggering a Health Crisis for Gen Z, Two Women Fought to Change India's Maternity Laws...and Succeeded,Can India Truly End Naxalism?, Semaglutide Goes Generic: Big Pharma’s Moat Breaks  and much more.

Catch the latest episode of ‘The Morning Brief’ on The Economic Times Online, Spotify, Apple Podcasts, JioSaavn, Amazon Music and Youtube.

India's rapidly expanding financial ecosystem faces a growing cybersecurity challenge. While large banks have invested heavily in protecting their systems, fintech companies and non-banking financial institutions remain vulnerable to increasingly sophisticated attacks. Artificial intelligence is changing the economics of cybercrime, allowing attackers to identify weaknesses faster, at significantly lower costs and on a much larger scale.
Anirban Chowdhury speaks to Yash Kakadia, founder of Security Brigade, about how these attacks work, the vulnerabilities within financial technology infrastructure, the limitations of compliance-driven security, and whether India's regulators and financial institutions can keep pace with an accelerating threat.
You can follow Anirban Chowdhury on his social media:<a href="https://twitter.com/AnirbanET"> X</a> and<a href="https://www.linkedin.com/in/anirban-chowdhury-b5067219/"> Linkedin </a>Check out other interesting episodes like:<a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777?i=1000742733036"> How Will a Volatile ₹ Impact You in 2026?</a>,<a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777?i=1000740924439"> How Quick Commerce is Triggering a Health Crisis for Gen Z</a>, <a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777?i=1000760362789">Two Women Fought to Change India's Maternity Laws...and Succeeded</a>,<a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777?i=1000738205536"> </a><a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777?i=1000757611462">Can India Truly End Naxalism?</a>, <a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777?i=1000756051799">Semaglutide Goes Generic: Big Pharma&rsquo;s Moat Breaks</a>&nbsp; and<a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777"> much more</a>.
Catch the latest episode of &lsquo;The Morning Brief&rsquo; on<a href="https://economictimes.indiatimes.com/podcast?from=mdr"> The Economic Times Online</a>,<a href="https://open.spotify.com/show/6PL5kfPbwURBEu6fHCVTOL?si=26ec0fbfa7134fea"> Spotify</a>,<a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777"> Apple Podcasts</a>,<a href="https://www.jiosaavn.com/shows/the-morning-brief/1/GNPiFQD2xpY_"> JioSaavn</a>,<a href="https://music.amazon.in/podcasts/f378141f-9afb-495d-83da-9b08ec5047ac/the-morning-brief"> Amazon Music</a> and<a href="https://www.youtube.com/@theetpodcasts"> Youtube</a>.

India's Banks Under Cyberattack: How AI Is Changing the Game

NPPA Margin Cap Explained

Why Some Prices Stay High

Patented Drugs and MNC Logic

Will Savings Reach Patients

Hospitals Oversight and What Next

Why does a cancer injection bought by a hospital for ₹11,000 end up costing a patient ₹1.3 lakh? India’s drug pricing system is under scrutiny as the government caps trade margins on hundreds of cancer medicines at 30%. While prices of several drugs have fallen sharply, nearly one in four packs has seen no reduction. And a 30% margin still allows a markup of nearly 43% over the manufacturer’s price. So who profits from expensive medicines? Why have previous interventions failed? And will the latest price cuts actually bring relief to patients? Anirban Chowdhury talks to ET's pharma editor Vikas Dandekar. Listen in:

You can follow Anirban Chowdhury on his social media: X and Linkedin

Check out other interesting episodes like: How Will a Volatile ₹ Impact You in 2026?, How Quick Commerce is Triggering a Health Crisis for Gen Z, Two Women Fought to Change India's Maternity Laws...and Succeeded,Can India Truly End Naxalism?, Semaglutide Goes Generic: Big Pharma’s Moat Breaks  and much more.

 

Catch the latest episode of ‘The Morning Brief’ on The Economic Times Online, Spotify, Apple Podcasts, JioSaavn, Amazon Music and Youtube.

Why does a cancer injection bought by a hospital for ₹11,000 end up costing a patient ₹1.3 lakh? India&rsquo;s drug pricing system is under scrutiny as the government caps trade margins on hundreds of cancer medicines at 30%. While prices of several drugs have fallen sharply, nearly one in four packs has seen no reduction. And a 30% margin still allows a markup of nearly 43% over the manufacturer&rsquo;s price. So who profits from expensive medicines? Why have previous interventions failed? And will the latest price cuts actually bring relief to patients? Anirban Chowdhury talks to ET's pharma editor Vikas Dandekar. Listen in: You can follow Anirban Chowdhury on his social media:<a href="https://twitter.com/AnirbanET"> X</a> and<a href="https://www.linkedin.com/in/anirban-chowdhury-b5067219/"> Linkedin </a>Check out other interesting episodes like:<a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777?i=1000742733036"> How Will a Volatile ₹ Impact You in 2026?</a>,<a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777?i=1000740924439"> How Quick Commerce is Triggering a Health Crisis for Gen Z</a>, <a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777?i=1000760362789">Two Women Fought to Change India's Maternity Laws...and Succeeded</a>,<a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777?i=1000738205536"> </a><a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777?i=1000757611462">Can India Truly End Naxalism?</a>, <a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777?i=1000756051799">Semaglutide Goes Generic: Big Pharma&rsquo;s Moat Breaks</a>&nbsp; and<a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777"> much more</a>.
&nbsp;
Catch the latest episode of &lsquo;The Morning Brief&rsquo; on<a href="https://economictimes.indiatimes.com/podcast?from=mdr"> The Economic Times Online</a>,<a href="https://open.spotify.com/show/6PL5kfPbwURBEu6fHCVTOL?si=26ec0fbfa7134fea"> Spotify</a>,<a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777"> Apple Podcasts</a>,<a href="https://www.jiosaavn.com/shows/the-morning-brief/1/GNPiFQD2xpY_"> JioSaavn</a>,<a href="https://music.amazon.in/podcasts/f378141f-9afb-495d-83da-9b08ec5047ac/the-morning-brief"> Amazon Music</a> and<a href="https://www.youtube.com/@theetpodcasts"> Youtube</a>.

The Cancer Drug Price Trap

How Agents Reshape Commerce

India Economics and Vertical Agents

Outcome Based Pricing

Enterprise Meets Personal Agents

Real Life AI Assistant Stories

When AI agents book your flights, buy your groceries and pick your hotels, no one is scrolling, and no one sees an ad. So how does the internet make money?

Lightspeed India partners Harsha Kumar and Hemanth Mohapatra explain which purchases agents will take over and which will stay human. They also cover why you can’t upsell an AI agent, what that means for the ad-based internet, and why India may prefer paying per outcome over subscriptions. They make the case for vertical AI built for tier-two and tier-three India, compare today’s AI wave with the dot-com era, and share how they use AI assistants themselves.

Tune in.

You can follow Himanshi Lohchab on her social media: X and Linkedin

 

Check out other interesting episodes like: How Will a Volatile ₹ Impact You in 2026?, How Quick Commerce is Triggering a Health Crisis for Gen Z, Two Women Fought to Change India's Maternity Laws...and Succeeded,Can India Truly End Naxalism?, Semaglutide Goes Generic: Big Pharma’s Moat Breaks  and much more.

 

Catch the latest episode of ‘The Morning Brief’ on The Economic Times Online, Spotify, Apple Podcasts, JioSaavn, Amazon Music and Youtube.

When AI agents book your flights, buy your groceries and pick your hotels, no one is scrolling, and no one sees an ad. So how does the internet make money?
Lightspeed India partners Harsha Kumar and Hemanth Mohapatra explain which purchases agents will take over and which will stay human. They also cover why you can&rsquo;t upsell an AI agent, what that means for the ad-based internet, and why India may prefer paying per outcome over subscriptions. They make the case for vertical AI built for tier-two and tier-three India, compare today&rsquo;s AI wave with the dot-com era, and share how they use AI assistants themselves. Tune in. You can follow Himanshi Lohchab on her social media: <a href="https://x.com/HimanshiET">X</a> and <a href="https://www.linkedin.com/in/himanshi-lohchab-751804173/">Linkedin</a>
&nbsp;
Check out other interesting episodes like:<a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777?i=1000742733036"> How Will a Volatile ₹ Impact You in 2026?</a>,<a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777?i=1000740924439"> How Quick Commerce is Triggering a Health Crisis for Gen Z</a>, <a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777?i=1000760362789">Two Women Fought to Change India's Maternity Laws...and Succeeded</a>,<a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777?i=1000738205536"> </a><a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777?i=1000757611462">Can India Truly End Naxalism?</a>, <a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777?i=1000756051799">Semaglutide Goes Generic: Big Pharma&rsquo;s Moat Breaks</a>&nbsp; and<a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777"> much more</a>.
&nbsp;
Catch the latest episode of &lsquo;The Morning Brief&rsquo; on<a href="https://economictimes.indiatimes.com/podcast?from=mdr"> The Economic Times Online</a>,<a href="https://open.spotify.com/show/6PL5kfPbwURBEu6fHCVTOL?si=26ec0fbfa7134fea"> Spotify</a>,<a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777"> Apple Podcasts</a>,<a href="https://www.jiosaavn.com/shows/the-morning-brief/1/GNPiFQD2xpY_"> JioSaavn</a>,<a href="https://music.amazon.in/podcasts/f378141f-9afb-495d-83da-9b08ec5047ac/the-morning-brief"> Amazon Music</a> and<a href="https://www.youtube.com/@theetpodcasts"> Youtube</a>.

AI Agents Are Breaking the Internet’s Ad Model

China Enters Biopharma

What Is Biopharma

America’s Biotech Head Start

Breakthrough Drugs Explained

China’s 2015 Biotech Surge

In Licensing Deals 101

China’s Cost Speed Advantage

Washington’s Security Alarm

Is There IP Theft

India’s Opportunity Window

What Happens Next

Wrap Up And Credits

China challenged America's dominance in manufacturing, technology and artificial intelligence. Now, it is threatening another American stronghold: the pharmaceutical industry.

Chinese biotech companies are developing breakthrough drugs faster and cheaper than their American counterparts. One Chinese cancer drug, ivonescimab, is emerging as a potential challenger to Keytruda, Merck's $31-billion blockbuster. Meanwhile, Western pharmaceutical giants are striking multibillion-dollar licensing deals with Chinese innovators.

But Washington is worried. Could America's growing dependence on Chinese biotechnology become a national security threat? And could India benefit from this escalating rivalry?

In this episode of The Morning Brief Decode, Anirban Chowdhury speaks to The Economic Times' pharma editor Vikas Dandekar about China's biotech revolution, the battle for the future of medicine, the US response and India's opportunity to become a bigger player in global drug innovation.

China challenged America's dominance in manufacturing, technology and artificial intelligence. Now, it is threatening another American stronghold: the pharmaceutical industry.
Chinese biotech companies are developing breakthrough drugs faster and cheaper than their American counterparts. One Chinese cancer drug, ivonescimab, is emerging as a potential challenger to Keytruda, Merck's $31-billion blockbuster. Meanwhile, Western pharmaceutical giants are striking multibillion-dollar licensing deals with Chinese innovators.
But Washington is worried. Could America's growing dependence on Chinese biotechnology become a national security threat? And could India benefit from this escalating rivalry?
In this episode of The Morning Brief Decode, Anirban Chowdhury speaks to The Economic Times' pharma editor Vikas Dandekar about China's biotech revolution, the battle for the future of medicine, the US response and India's opportunity to become a bigger player in global drug innovation.

China vs US: The New War Over Cancer Drugs and Biotech Supremacy | The Morning Brief Decode

Shipments Hit Decade Low

Why Phones Got Pricier

Is This A Bigger Worry

 India Near Saturation

Inside The Memory Crunch

Consumers Trade Down

 Feature Cuts And Margins

AI Data Centers Squeeze

Zooming Out To Consumption

Inflation And Household Budgets

Jobs But Weak Spending

What The Slowdown Means

Wrap Up And Sign Off

India’s smartphone market is heading into Diwali on a sour note. Shipments fell sharply in the July–September quarter, with the sub-₹20,000 segment hit hardest. A global memory-chip crunch is raising costs, pushing up prices and forcing buyers to delay upgrades, settle for fewer features or choose refurbished phones. But does this slump signal a wider squeeze on household spending, or is it a supply shock tied to the race to build AI data centres? We examine what falling shipments reveal about affordability, consumption and India’s mobile growth, with Counterpoint Research’s Tarun Pathak and Bank of Baroda chief economist Madan Sabnavis.

India&rsquo;s smartphone market is heading into Diwali on a sour note. Shipments fell sharply in the July&ndash;September quarter, with the sub-₹20,000 segment hit hardest. A global memory-chip crunch is raising costs, pushing up prices and forcing buyers to delay upgrades, settle for fewer features or choose refurbished phones. But does this slump signal a wider squeeze on household spending, or is it a supply shock tied to the race to build AI data centres? We examine what falling shipments reveal about affordability, consumption and India&rsquo;s mobile growth, with Counterpoint Research&rsquo;s Tarun Pathak and Bank of Baroda chief economist Madan Sabnavis.

Does Slumping Smartphone Demand Spell a Gloomy Diwali?

Vibe Coding Revolution

Mukund and Emergent Rise

Who Gets to Build

From Simple Apps to Superapps

Contrarian Founder Mindset

Origin Insight Coding Agents

Dunzo Lessons Growth Endurance

Second Mover Edge in AI

End to End Hosting Advantage

Democratizing Software for SMBs

Risks Cyberattacks Misalignment

AI Risks and Trust

Small Business Adoption

Quirky AI Use Cases

Local Builders Rising

Moats in AI Platforms

 Hypergrowth Economics

Improving Margins

Tracking App Success

IPO and Profitability

VibeCon Global Vision

Future of Builders

Closing Credits

What if you didn’t need a tech team, or any code, to build software?
In this episode of Corner Office Conversation, Anirban Chowdhury sits down with Mukund Jha, Founder and CEO of Emergent, the AI platform where anyone with an idea can build a real, hosted, working app. A former Google engineer, Mukund also co-founded Dunzo, the unicorn that became a verb in India...and then folded.
He shares hard-won Dunzo lessons on growth versus endurance, focus and unit economics, and why second-mover advantage matters in AI. Emergent says 18 million apps have been built on it. Mukund believes anyone could soon build any software without code.

What if you didn&rsquo;t need a tech team, or any code, to build software? In this episode of Corner Office Conversation, Anirban Chowdhury sits down with Mukund Jha, Founder and CEO of Emergent, the AI platform where anyone with an idea can build a real, hosted, working app. A former Google engineer, Mukund also co-founded Dunzo, the unicorn that became a verb in India...and then folded. He shares hard-won Dunzo lessons on growth versus endurance, focus and unit economics, and why second-mover advantage matters in AI. Emergent says 18 million apps have been built on it. Mukund believes anyone could soon build any software without code.

The $1.5 Billion Bet on a World Without Coders | Emergent’s Mukund Jha

AT1 Bonds Shockwave

Yes Bank Write Down Case

India vs Switzerland Parallel

Meet the Expert Guest

Supreme Court Surprise Ruling

What Are AT1 Bonds

Why AT1s Turn Controversial

RBI Rules and Footnote

Moratorium and Draft Plan Twist

Swiss Court Logic Explained

 Bystanders and RBI Accountability

What Yes Bank Does Next

Future of AT1 Investing

Wrap Up and Credits

The Supreme Court has set aside Yes Bank’s 2020 write-down of ₹8,415 crore in AT1 bonds. Anirban Chowdhury speaks to Sugata Ghosh of The Economic Times about how AT1 bonds work, why the Court ruled against the write-down, what the judgment means for investors and regulators, and how the case compares with Switzerland’s Credit Suisse AT1 dispute

The Supreme Court has set aside Yes Bank&rsquo;s 2020 write-down of ₹8,415 crore in AT1 bonds. Anirban Chowdhury speaks to Sugata Ghosh of The Economic Times about how AT1 bonds work, why the Court ruled against the write-down, what the judgment means for investors and regulators, and how the case compares with Switzerland&rsquo;s Credit Suisse AT1 dispute

Yes Bank AT1 Bonds: Why the Supreme Court Reversed the ₹8,415 Crore Write-Down

To make sense of the week’s hottest stories in business, economy, politics and markets, journalists from the Economic Times chat with reporters and industry leaders in this thrice-weekly (Tuesday, Thursday, Friday) podcast.

The Morning Brief

The Morning Brief

Social links:

Follow the podcast:

1,059 clip(s)